Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

Three biotechs dis­closed pull­backs on sick­le cell dis­ease R&D in the span of 16 hours: with Graphite Bio end­ing work, Sang­amo Ther­a­peu­tics search­ing for a pro­gram part­ner and In­tel­lia Ther­a­peu­tics say­ing No­var­tis re­neged on an ear­ly-phase clin­i­cal tri­al.

The pipeline rewrites come as Ver­tex and part­ner CRISPR Ther­a­peu­tics wrap up an ap­proval re­quest for their ex vi­vo gene-edit­ed ther­a­py and as blue­bird bio sends in the pa­per­work for an FDA green light of its gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER